SHTDY (Sinopharm Group Co) Retained Earnings: $8,345 Mil (As of Dec. 2025)


SHTDY Sinopharm Group Co Ltd SHTDY
73 GF Score
Price $10.68
GF Value $13.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Retained Earnings?

Sinopharm Group Co SHTDY -1.84% 73 Retained Earnings is $8,345 Mil as of Dec. 2025. GuruFocus rates SHTDY with a GF Score™ of 73/100 and a GF Value™ of $13.64 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sinopharm Group Co's retained earnings for the quarter that ended in Dec. 2025 was $8,345 Mil.

Sinopharm Group Co's quarterly retained earnings increased from Dec. 2024 ($7,382 Mil) to Jun. 2025 ($7,672 Mil) and increased from Jun. 2025 ($7,672 Mil) to Dec. 2025 ($8,345 Mil).

Sinopharm Group Co's annual retained earnings increased from Dec. 2023 ($6,920 Mil) to Dec. 2024 ($7,382 Mil) and increased from Dec. 2024 ($7,382 Mil) to Dec. 2025 ($8,345 Mil).


Sinopharm Group Co  (OTCPK:SHTDY) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Sinopharm Group Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Retained Earnings Chart

Sinopharm Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 6,155.41 6,919.98 7,381.83 8,345.36

Sinopharm Group Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,919.98 6,947.08 7,381.83 7,672.07 8,345.36
SHTDY
73GF Score
Sinopharm Group Co Ltd SHTDY
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Group Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $8,345 Mil mean?
Sinopharm Group Co (SHTDY) has a Retained Earnings of $8,345 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Retained Earnings too high?
Sinopharm Group Co's current Retained Earnings is $8,345 Mil. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Retained Earnings compare to MCK and CAH?
Sinopharm Group Co's Retained Earnings of $8,345 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Distribution company?
A good Retained Earnings depends on the Medical Distribution industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Retained Earnings is $8,345 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.64, compared to a current price of $10.68 — trading 21.7% below its estimated fair value. The current Retained Earnings is $8,345 Mil. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Retained Earnings is $8,345 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDY) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $10.68 is trading 21.7% below its estimated GF Value™ of $13.64. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDY:

  • Retained Earnings: $8,345 Mil
  • GF Value™: $13.64 vs. price of $10.68 (21.7% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score

Get the complete analysis for SHTDY

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.68
Price
$13.64
GF Value